Literature DB >> 2117187

Natural history of obstructive airways disease and hypoxia: implications for therapy.

P Howard1.   

Abstract

Chronic irreversible obstructive airways disease (COAD) is the end result of a number of disorders: airway damage from tobacco smoke, atmospheric pollution and occupational dust and fume, bronchiectasis, cystic fibrosis, bronchial asthma and a number of congenital disorders of defective airway defence. The clinical features include sputum, wheeze, breathlessness and infective and noninfective airway inflammation. The pathological consequences are airways obstruction, emphysema and respiratory failure. Except in bronchiectasis, the volume of daily sputum and bronchial infection is less than 20-30 years ago. At autopsy, bronchial gland hypertrophy is now an inconstant feature. Bronchial infection probably contributes little to airways obstruction, but the load of activated neutrophils in bronchiectasis is an important feature. Wheeze comes late to many patients with COAD. It is associated with less reversibility to bronchodilator drugs and more fixed airways obstruction compared to the conventional asthmatic and is probably of different aetiology. Breathlessness is of variable severity when the forced expiratory volume (FEV1) falls below 1.0 liters resulting in disability ranging from manageable to severe. The FEV1 declines an average by 70-80 ml/year (normal approx. 25 ml/year) until the value falls below 1.0 liters, then the rate of decline slows to a plateau which can persist for several years. During this period, hyperinflation, breathlessness and respiratory failure continue to worsen. Significant respiratory failure may be a terminal event or be present for many years. Arterial oxygen tension (PaO2) slowly declines in most patients--"pink puffers" generally have a minimal rate of fall until weeks or months before death, "blue bloaters," by contrast, several times as great.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1990        PMID: 2117187     DOI: 10.1007/bf02718203

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  7 in total

1.  The natural history of chronic airflow obstruction.

Authors:  C Fletcher; R Peto
Journal:  Br Med J       Date:  1977-06-25

2.  Almitrine bismesylate: a long-term placebo-controlled double-blind study in COAD--Vectarion International Multicentre Study Group.

Authors:  C Voisin; P Howard; J C Ansquer
Journal:  Bull Eur Physiopathol Respir       Date:  1987-08

3.  Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party.

Authors: 
Journal:  Lancet       Date:  1981-03-28       Impact factor: 79.321

4.  Pulmonary hemodynamics, gas exchange, and the severity of emphysema as assessed by quantitative CT scan in chronic bronchitis and emphysema.

Authors:  W Biernacki; G A Gould; K F Whyte; D C Flenley
Journal:  Am Rev Respir Dis       Date:  1989-06

5.  Intermittent positive pressure breathing therapy of chronic obstructive pulmonary disease. A clinical trial.

Authors: 
Journal:  Ann Intern Med       Date:  1983-11       Impact factor: 25.391

6.  Twelve year clinical study of patients with hypoxic cor pulmonale given long term domiciliary oxygen therapy.

Authors:  C B Cooper; J Waterhouse; P Howard
Journal:  Thorax       Date:  1987-02       Impact factor: 9.139

7.  Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group.

Authors: 
Journal:  Ann Intern Med       Date:  1980-09       Impact factor: 25.391

  7 in total
  1 in total

1.  Firing probability and mean firing rates of human muscle vasoconstrictor neurones are elevated during chronic asphyxia.

Authors:  Cynthia Ashley; Danielle Burton; Yrsa B Sverrisdottir; Mikael Sander; David K McKenzie; Vaughan G Macefield
Journal:  J Physiol       Date:  2010-01-05       Impact factor: 5.182

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.